Gabrielle V Ronnett

20050143467, Jun 30, 2005

Feb 10, 2003

10/503605

Jagan Thupari - Owings Mills MD, US
Gabrielle Ronnett - Lutherville MD, US
Francis Kuhajda - Lutherville MD, US

The Johns Hopkins University School of Medicine Licensing and Technology Development - Baltimore MD

A61K031/198
A61K031/365

514565000, 514471000

This invention provides methods and compositions for inducing weight loss and maintaining optimum weight comprising administering an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity to the patient in need, including human patients. These methods do not require inhibition of fatty acid synthesis. In particular, this invention provides methods for development of therapeutics that selectively enhance fatty acid oxidation, increase energy production, and reduce adiposity while preserving lean mass, through the pharmacological stimulation of CPT-1 activity. In a preferred mode, the agent is administered in an amount sufficient to increase fatty acid oxidation. In another preferred mode, the agent is administered in an amount sufficient to antagonize malonyl CoA inhibition of CPT-1. In yet another preferred mode, the agent is administered in an amount sufficient to increase malonyl CoA level.

20070087037, Apr 19, 2007

Oct 2, 2006

11/537968

Jagan THUPARI - Owings Mills MD, US
Leslie Landree - Baltimore MD, US
Gabrielle Ronnett - Lutherville MD, US
Francis Kuhajda - Lutherville MD, US

The Johns Hopkins University School of Medicine Licensing and Technology Development - Baltimore MD

A61K 47/00
A61K 31/205

424439000, 514554000

This invention provides methods and compositions for inducing weight loss and maintaining optimum weight comprising administering an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity to the patient in need, including human patients. These methods do not require inhibition of fatty acid synthesis. In particular, this invention provides methods for development of therapeutics that selectively enhance fatty acid oxidation, increase energy production, and reduce adiposity while preserving lean mass, through the pharmacological stimulation of CPT-1 activity. In a preferred mode, the agent is administered in an amount sufficient to increase fatty acid oxidation. In another preferred mode, the agent is administered in an amount sufficient to antagonize malonyl CoA inhibition of CPT-1. In yet another preferred mode, the agent is administered in an amount sufficient to increase malonyl CoA level.

20070197638, Aug 23, 2007

Jan 25, 2007

11/657536

Thomas Loftus - Great Falls VA, US
Craig Townsend - Baltimore MD, US
Gabrielle Ronnett - Lutherville MD, US
M. Lane - Baltimore MD, US
Francis Kuhajda - Lutherville MD, US

The Johns Hopkins University School of Medicine Licensing and Technology Development - Baltimore MD

A61K 31/365
C12Q 1/68

514473000, 435006000

This invention provides a method for inducing weight loss in an animal by administering to the animal a compound which reduces the expression and/or secretion of neuropeptide Y (NPY). The effect may be accomplished directly, indirectly, or humorally. Preferably, administration of this compound has the effect of increasing malonyl CoA levels in the animal. Compounds administered according to this invention may be inhibitors of fatty acid synthase (FAS), including substituted α-methylene-β-carboxyl-γ-butyrolactones, or inhibitors of malonyl Coenzyme A decarboxylase (MCD). Preferably, the compound is administered in an amount sufficient to reduce the amount and/or duration of expression and/or secretion of NPY to levels at or below those observed for lean animals. In another preferred embodiment, the administration will reduce expression and/or secretion to levels observed for fed or satiated animals; more preferably, administration will reduce the level of NPY below that of fed animals. In a particular embodiment, this invention provides a method for inducing weight loss in an animal by administering a compound which inhibits feeding behavior in the animal. The method is particularly useful for inducing weight loss in animals deficient in expression of the hormone leptin or animals resistant to the action of leptin.

20080119548, May 22, 2008

Mar 18, 2005

10/593090

Gabrielle V. Ronnett - Baltimore MD, US
Frankcis P. Kuhajda - Baltimore MD, US
Jagan N. Thupari - Baltimore MD, US
Leslie E. Landree - Baltimore MD, US
Timothy H. Moran - Baltimore MD, US
Eun-Kyoung Kim - Baltimore MS, US

A61K 31/341
A61P 3/04

514473

Obesity is a worldwide health issue, affecting children and adults in developed and developing countries. Obesity is a disorder of both energy metabolism and appetite regulation, and may be understood as a dysfunction of energy balance. Applicants have found a means for regulating food intake by a subject by administering a compound to the subject which affects neuronal energy balance. Applicants have found a means for regulating food intake by a subject administering a compound to the subject which targets the activity of AMPK, in particular inhibiting activation, in particular hypothalamic. Applicants have also found a method of inducing weight loss in a subject by decreasing the subjects appetite by administering a compound to the subject which increases the subject's neuronal energy balance.

20090124684, May 14, 2009

Nov 6, 2008

12/266425

Jagan N. Thupari - Owings Mills MD, US
Leslie E. Landree - Baltimore MD, US
Gabrielle Ronnett - Lutherville MD, US
Francis P. Kuhajda - Lutherville MD, US

The Johns Hopkins University School of Medicine Licensing and Technology Development - Baltimore MD

A61K 31/381
A61K 31/365
C12Q 1/48

514445, 514473, 435 15

This invention provides methods and compositions for inducing weight loss and maintaining optimum weight comprising administering an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity to the patient in need, including human patients. These methods do not require inhibition of fatty acid synthesis. In particular, this invention provides methods for development of therapeutics that selectively enhance fatty acid oxidation, increase energy production, and reduce adiposity while preserving lean mass, through the pharmacological stimulation of CPT-1 activity. In a preferred mode, the agent is administered in an amount sufficient to increase fatty acid oxidation. In another preferred mode, the agent is administered in an amount sufficient to antagonize malonyl CoA inhibition of CPT-1. In yet another preferred mode, the agent is administered in an amount sufficient to increase malonyl CoA level.

20140243401, Aug 28, 2014

Nov 23, 2011

13/989731

Gabrielle Ronnett - Lutherville MD, US
Craig Townsend - Baltimore MD, US

The Johns Hopkins University - Baltimore MD

G01N 33/50

514445, 435 32, 435375

The invention relates to methods of screening to find compounds that are cytotoxic to tumor cells and methods of treating tumor cells using these compounds. In particular, the invention relates to methods of screening for compounds that inhibit mammalian mitochondrial fatty acid synthase (mmFAS) and methods of treating tumor cells using mmFAS inhibitors. This invention also provides methods for inhibiting or preventing cancer cell survival by the administration of mitochondrial fatty acid synthase (FAS) inhibitors. Specifically, this invention describes a method for prohibiting or delaying the development of cancer, the growth of cancer or invasion of cancer from pre-malignant (noninvasive) lesions, or metastasis of cancer based upon the findings that this method compromises energy balance in cancer cells, in turn compromising their basic functions and causing their cell death. Compositions of matter containing mitochondrial FAS inhibition activity are also provided, as well as applications based upon the requisite role of mitochondrial FAS in cancer cell homeostasis.